Phase 1 Trial of Panobinostat + Ruxolitnib for Relapsed/Refactory Diffused Large B Cell Lymphoma (DLBCL)

Administered By

Awarded By

Contributors

Start/End

  • March 1, 2016 - August 31, 2019